VN1R31P

Across TCGA pan-cancer cohorts, VN1R31P RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated VN1R31P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher VN1R31P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated VN1R31P expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LIHC, READ, and BLCA are the cancer types where VN1R31P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.118	0.783	<.001	45	view →
READ	DFS	Tertile	All	0.112	0.845	.001	36	view →
BLCA	OS	Tertile	IV	0.506	0.285	<.001	30	view →
KIRP	OS	Tertile	All	0.766	0.935	.018	27	view →
THCA	DFS	Tertile	II,III,IV	0.145	0.794	.001	18	view →
BRCA	DFS	Tertile	All	0.772	0.903	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

VN1R31P–LIHC (OS)

Open the LIHC breakdown →